Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
Adult
Aged
Antigens, CD34
/ analysis
Benzylamines
Cyclams
Hematologic Neoplasms
/ therapy
Hematopoietic Stem Cell Mobilization
/ methods
Hematopoietic Stem Cell Transplantation
/ methods
Heterocyclic Compounds
/ therapeutic use
Histocompatibility
Humans
Middle Aged
Siblings
Tissue Donors
Transplantation, Homologous
Treatment Outcome
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
26 03 2019
26 03 2019
Historique:
received:
22
10
2018
accepted:
11
02
2019
entrez:
21
3
2019
pubmed:
21
3
2019
medline:
28
3
2020
Statut:
ppublish
Résumé
Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 µg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of ≥2.0 × 10
Identifiants
pubmed: 30890544
pii: bloodadvances.2018027599
doi: 10.1182/bloodadvances.2018027599
pmc: PMC6436017
doi:
Substances chimiques
Antigens, CD34
0
Benzylamines
0
Cyclams
0
Heterocyclic Compounds
0
plerixafor
S915P5499N
Banques de données
ClinicalTrials.gov
['NCT01696461']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
875-883Subventions
Organisme : NCI NIH HHS
ID : R01 CA188523
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NHLBI NIH HHS
ID : U24 HL138660
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA138292
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210084
Pays : United States
Informations de copyright
© 2019 by The American Society of Hematology.
Références
J Clin Oncol. 2005 Aug 1;23(22):5074-87
pubmed: 16051954
N Engl J Med. 2006 Apr 27;354(17):1813-26
pubmed: 16641398
Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56
pubmed: 16338616
Blood. 2008 Aug 15;112(4):990-8
pubmed: 18426988
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2009 Jun 4;113(23):5720-6
pubmed: 19363221
Blood. 2017 May 11;129(19):2680-2692
pubmed: 28292947
Biol Blood Marrow Transplant. 2017 Jan;23(1):165-171
pubmed: 27751935
J Clin Oncol. 2009 Oct 1;27(28):4767-73
pubmed: 19720922
Cell. 2018 Jan 11;172(1-2):191-204.e10
pubmed: 29224778
Blood. 2015 Feb 19;125(8):1333-8
pubmed: 25593335
J Clin Oncol. 2015 Jul 20;33(21):2392-8
pubmed: 26056179
J Clin Oncol. 2014 Aug 1;32(22):2365-72
pubmed: 24982459
Blood. 2009 Apr 9;113(15):3604-11
pubmed: 19190248
N Engl J Med. 2012 Oct 18;367(16):1487-96
pubmed: 23075175